Anti-cancer drug bexarotene (Tagretin), which had extremely promising results in reversing Alzheimer's disease symptoms in mice last year, was found not to be as promising in later trials, according to articles published in the journal Science. In other words, scientists have not able to fully replicate the original findings. Last year, researchers from Case Western Reserve University claimed that bexarotene cleared amyloid plaques from the brains of transgenic laboratory mice...
Monday, 27 May 2013
12:13
nitin
cyber network news, health news, news
No comments
Related Posts:
Snoop Lion and Miley Cyrus Sing About 'Ashtrays and Heartbreaks' Snoop Lion, fresh off teaming up with Mashable for a Twitter chat Q&A, has unleashed his somber "Ashtrays and Heartbreaks" music video, featuring Miley Cyrus.Together, they rap and sing about filling up ashtrays, wit… Read More
Julius Richard Petri Receives The Google Doodle HonorGoogle is running a homepage doodle honoring German bacteriologist Julius Richard Petri in parts of the world where the date has already changed to May 31st.The date marks the 160th birthday of the scientist, who is known as … Read More
Vine User Creates Elaborate Snoopy Animation for New 'Peanuts' Movie Khoa Phan, know for his stop-motion animations on Vine, has finished his first creation for Peanuts Worldwide as part of a 12-Vine deal he inked with the company to promote the still-untitled 3D animated movie based on Cha… Read More
Two GSK Skin Cancer Drugs Approved By FDATwo new GlaxoSmithKline (GSK) drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved for the treatment of patients with advanced melanoma by the U.S. Food and Drug Administration (FDA). Melanoma is the mos… Read More
Police: Man Lured Teenage Girl to Her Death With Fake Facebook Page A man indicted on murder charges set up a fake Facebook page to lure a teenage girl before kidnapping and killing her, according to police.Kyle Dube, 20, is accused of using Facebook in a bizarre scheme to kidnap 15-year-o… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment